Tetra Bio-Pharma Inc.
Tetra Bio-Pharma Inc., a biopharmaceutical company, engages in the discovery and development of immunomodulator drugs. The company develops PLENITUDE to treat cancer-related pain in advanced cancer patients; and REBORN for the treatment of breakthrough cancer pain. It also develops novel prescription drugs and treatments to relieve symptoms associated with advanced cancer pain, chronic pain, Acut… Read more
Tetra Bio-Pharma Inc. (TBPMQ) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of August 2022: 0.148x
Based on the latest financial reports, Tetra Bio-Pharma Inc. (TBPMQ) has a cash flow conversion efficiency ratio of 0.148x as of August 2022.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-873.53K) by net assets ($-5.91 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Tetra Bio-Pharma Inc. - Cash Flow Conversion Efficiency Trend (2019–2021)
This chart illustrates how Tetra Bio-Pharma Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Tetra Bio-Pharma Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tetra Bio-Pharma Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
VHABW
PINK:VHABW
|
3.317x |
|
IQ-AI LTD. LS -01
F:5Y1
|
N/A |
|
Pioneer High Income Closed Fund
NYSE:PHT
|
0.046x |
|
EVOLUTION MIN
MU:WE7
|
N/A |
|
Cemex SAB de CV
STU:CEXA
|
0.143x |
|
Il-Yang Pharmaceutical Co. Ltd.
KQ:007570
|
N/A |
|
XPS Pensions Group PLC
LSE:XPS
|
0.082x |
|
CI Com SA
SW:CIE
|
0.020x |
Annual Cash Flow Conversion Efficiency for Tetra Bio-Pharma Inc. (2019–2021)
The table below shows the annual cash flow conversion efficiency of Tetra Bio-Pharma Inc. from 2019 to 2021.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2021-11-30 | $249.33K | $-25.28 Million | -101.374x | -11561.76% |
| 2020-11-30 | $22.59 Million | $-19.64 Million | -0.869x | -23.56% |
| 2019-11-30 | $24.65 Million | $-17.34 Million | -0.704x | -- |